BPGbio’s Interrogative Biology® platform continues to demonstrate its unrivaled capability and speed in how medicines are discovered, allowing BPGbio to secure a robust portfolio of more than 400 US and international granted and pending patents. The IP portfolio and our intelligent drug discovery process combined with a prolific clinical and diagnostics pipeline consisting of more than a dozen promising candidates validate and exemplify BPGbio’s approach of using patient biology and AI to bring new products to market.
A Rich Global Patent Portfolio
